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Abstract
Background and aims: Inflammatory bowel disease (IBD) is often one of the most devastating
and debilitating chronic gastrointestinal disorders in children and adolescents. The main
objectives were to systematically review the incidence and prevalence of paediatric
inflammatory bowel disease across all 51 European states.
Methods: A systematic review and meta analysis based on PubMed, CINAHL, the Cochrane
Library, searches of reference lists, grey literature and websites, covering the period from 1970
to 2018.
Results: Incidence rates for both paediatric Crohn’s disease (CD) and ulcerative colitis (UC)
were higher in northern Europe than in other European regions. There have been large
increases in the incidence of both paediatric CD and UC over the last 50 years, which appear
widespread across Europe. The largest increases for CD have been reported from Sweden,
Wales, England, the Czech Republic, Denmark and Hungary, and for UC from the Czech Republic,
Ireland, Sweden and Hungary.
Incidence rates for paediatric CD have increased up to 9 or 10 per 100 000 population in
parts of Europe, including Scandinavia, while rates for paediatric UC are often slightly lower
than for CD. Prevalence reported for CD ranged from 8.2 per 100 000 to approximately 60 and,
for UC, from 8.3 to approximately 30.
Conclusions: The incidence of paediatric IBD continues to increase throughout Europe. There
is stronger evidence of a north: south than an east: west gradient in incidence across Europe.
Further prospective studies are needed, preferably multinational and based on IBD registries,
using standardised definitions, methodology and timescales.
Key words: Inflammatory bowel disease, paediatric, Europe, incidence, trends
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Introduction
The incidence of inflammatory bowel disease (IBD) usually peaks during adolescence or early
adulthood with up to one quarter of all cases diagnosed before the age of 18 years.1-3 The
development of IBD during childhood, rather than adulthood, is thought to involve increased,
earlier exposure to environmental triggers and greater genetic susceptibility.4 Information on
patterns of paediatric IBD incidence over time and geographically across Europe can provide
insight as to whether changes in environmental factors are involved in modifying disease
pathology.  It can also be used to inform future resource allocation and for targeting services.  
In 2013, United European Gastroenterology commissioned the authors to review the disease
burden of all major gastrointestinal disorders and the organisation and delivery of
gastroenterology services across 35 European countries from 1990 to 2014.5 This systematic
review and meta analyses provides a more detailed, and focused analysis of the incidence and
prevalence of paediatric IBD across all 51 European states since 1970, updated to the end of
December 2018. 
There have been several previous reviews of the epidemiology of paediatric IBD,2-4,6,7 although
these have been worldwide in scope rather than focused on all European countries,2-4,6,7 were
structured or narrative rather than fully systematic reviews,3,4,6,7 or are now becoming dated.2
The main purpose of this review is to fill the gaps in the evidence base for paediatric IBD across
Europe, by providing a systematic review across all 51 European nation states to the end of
2018.  
Specific study objectives were, first, to systematically review the incidence and prevalence of
paediatric IBD across Europe from 1970 to 2018. Second, to assess regional variation in
paediatric IBD incidence and prevalence across Europe. Third, to analyse trends over time in
paediatric IBD incidence, overall and according to age group at disease onset; and, fourth, to





This systematic review covered all 51 European states across Europe, over the 49 year time
period from January 1st 1970 to December 31st 2018. There are few European studies of IBD
incidence or prevalence before 1970, they typically reported very low incidence of paediatric
IBD, based on few cases and are mostly from Scandinavia. Where study time periods overlapped
the 1960s and 1970s, only those with the majority of the study period since 1970 were
included. The review assessed Crohn’s disease (CD), ulcerative colitis (UC) and indeterminate
colitis (otherwise termed unclassified colitis) separately and included studies written in all
European languages.
To assess geographical patterns in paediatric IBD incidence across Europe, the 51 states were
grouped into the following four regions: 
• Northern Europe (Denmark, Finland, Iceland, Ireland, Norway, Sweden and the UK -
England, Wales, Scotland and Northern Ireland)
• Western Europe (Austria, Belgium, France, Germany, Liechtenstein, Luxembourg, Monaco,
the Netherlands and Switzerland)
• Eastern Europe (Armenia, Azerbaijan, Belarus, Bulgaria, the Czech Republic, Estonia,
Georgia, Hungary, Kazakhstan, Latvia, Lithuania, Moldova, Poland, Romania, Russia, Slovakia
and the Ukraine)
• Southern Europe (Albania, Andorra, Bosnia and Herzegovina, Croatia, Cyprus, Greece, Italy,
Kosovo, Macedonia, Montenegro, Malta, Portugal, San Marino, Serbia, Slovenia, Spain,
Turkey and the Vatican City)
Inclusion and exclusion criteria
This systematic review included reports on population-based incidence or prevalence of
paediatric IBD from cohort studies, patient case series or population-based studies. The review
included studies of paediatric and/or adolescent age ranges spanning from 0 years to 14, 15 or
up to 18 years, depending on the age ranges used in each study. Where it was not possible to
disaggregate the reported age groups, the review also included studies of ages up to 19 and, in
one case, 20 years.
The review excluded several types of study design. These were, firstly, studies based exclusively
on primary care consultations, as they can reflect health seeking behavioural patterns rather
than actual incidence of IBD. Secondly, the review excluded studies based solely on inpatient
admissions from administrative data as these often refer mainly to acute cases which do not
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cover all cases of IBD, while trends in their rates can reflect organisational changes in the
provision of inpatient care rather than actual changes in incidence. Third, a few studies based
solely on capture-recapture methodology were excluded as this method can be unreliable for
studies of human populations. Fourth, studies based entirely on health insurance data were
excluded, unless the population coverage of the insurance schemes was known to be
(approximately) complete so that the incidence and/or prevalence reported would be accurate.
Studies that covered <3 cases of IBD were also excluded. Where two publications reported
exactly the same incidence or prevalence of IBD from the same location during the same time
period, only the first study identified was included. The review excluded reports with study case
ascertainment and other methodology not described or described inadequately, including some
abstracts or other short publications and also studies that were not based on clinical diagnoses,
histopathology or radiological findings. Studies that covered limited age ranges, such as <10 or
10-19 years have been reported separately, as the incidence of IBD often increases sharply from
the ages of 10+ or 15+ years. 
Search criteria and data extraction
The systematic review used the PubMed, CINAHL and Cochrane Library medical literature
databases. The search terms used are listed in Appendix 1. Additional literature was identified
through hand searching of reference lists and searches of grey literature and websites. Eligible
studies were reviewed for inclusion against the stated inclusion and exclusion criteria and
STROBE guidelines.8 The review included literature published, in press or in the public domain
as of December 31st 2018.
The PRISMA flow diagram in Figure 1 shows the numbers of studies included at each stage of
screening for the review. The following data items were extracted using a designed data
extraction sheet: country and region, study design and information sources used, study time
period, patient age details, number of cases, population incidence and prevalence of IBD, study
authors and reference. When extracting information from the studies, pairs of
investigators/researchers consulted to compare findings and reach consensus. Where
consensus was not reached, another investigator was consulted.
Geographical and statistical methods
Geographical Information System (GIS) mapping was used to illustrate the incidence of
paediatric CD and UC across Europe. The software used was QGIS.9 In these maps, the countries
were grouped into quintiles according to incidence rates, with quintiles comprising equal
numbers of countries in each quintile. The incidence rates were based on a meta analysis of
rates from studies within each country, with precedence given to national or nationally
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representative studies and the most recent study time periods. In the absence of national
studies, incidence rates from other studies were combined and weighted by study size. In the
maps provided, only those countries based on national studies are shaded, with details of the
non-national studies provided separately in Tabular format.
Time trend analyses and mean annual changes in incidence rates were used to assess changes
over time in disease incidence. To eliminate possible biases from methodological variation
across studies, the time trend analyses were confined to comparisons within longitudinal
studies and excluded comparisons across different studies. The time trends were presented
graphically with mid points that were spaced, where possible, at approximately four years
apart. The review assessed trends in incidence according to the age group at disease onset,
which varied across studies from 0-5, 0-6, 0-7 and 0-10 years for early onset compared with
later onset age groups. Mean ratios of paediatric CD to UC incidence were assessed over time for
studies conducted either wholly, or mostly, during the three time periods 1970-1989, 1990-
1999 and since 2000.
To compare the incidence of paediatric CD and UC regionally across Europe since 2000, Fisher’s
Exact test was used to compare the numbers of studies based in the four regions of Europe
(east, west, north and south) that reported high or low incidence rates. High incidence was
defined as >3.0 per 100 000 population for paediatric CD and >2.5 per 100 000 for paediatric
UC. Incidence and prevalence rates were calculated using the numbers of paediatric IBD cases
as numerators, the resident paediatric populations as denominators and were expressed per
100 000 population. Significance was measured at the conventional 5% level.
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Results
Geographical coverage of studies across Europe included in the review
The numbers of studies and countries covered under each project objective are summarised for
each of the four regions of Europe in Table 1. Most of the evidence is from northern Europe,
largely from Denmark, Norway, Scotland and Sweden. Reports from western Europe are from
Austria, Belgium, France, Germany, Switzerland and The Netherlands, while in southern Europe,
most evidence is from Italy, Slovenia and Spain. Of the four European regions, there is least
literature from eastern Europe.  
Incidence of paediatric Crohn’s disease across Europe
Appendix 2 shows incidence and prevalence rates reported for paediatric CD split into two time
periods, 1970-1999 and 2000-2018. Since 2000, incidence has varied from 0.3 per 100 000
population in the Tuzla region of Bosnia & Herzegovina,10 to 10 per 100 000 in the Uppsala
region of Sweden.11 Other studies that have reported highest incidence of paediatric CD in
recent years refer to Denmark nationally (9.7),12 4 departments of northern France (9.3),13
Stockholm County, Sweden (9.2),14 along with Primorsko-Goranska County, Croatia (8 per 100
000),15 and Veszprem province of Hungary (7.2).16
During the earlier time period from 1970 to 1999, incidence was usually lower than in recent
years, with highest incidence reported from Stockholm County, Sweden (4.9 per 100 000),17
Iceland nationally (4.5),18 south Limburg in The Netherlands (4.2),19 northern France (4.1),13
and the Faroe Islands (4).20
Most studies that have reported high incidence of paediatric CD (>3 per 100 000) are from
northern Europe, particularly Scandinavia, and most that have reported low incidence (≤3 per
100 000) are from southern Europe, with the notable exception of Slovenia, or eastern Europe.
Since 2000, 17 of 21 studies from northern Europe (81%) reported high incidence, which is
greater than 3 of 12 studies (25%) from southern Europe (p=0.003), but not significantly higher
than 56% of 9 studies from eastern Europe (p=0.195), or 71% of 7 studies from western Europe
(p=0.621). Overall, the proportion of studies reporting high incidence in northern Europe (81%)
was higher than for the other three regions of Europe combined (46%; p=0.019). 
Table 2 and Figure 2a illustrate a meta analysis of paediatric CD incidence reported across
Europe since 2000. This shows the highest incidence quintile largely based on studies from
parts of Scandinavia (Denmark, Norway and Sweden) Croatia and France, and lowest incidence
in studies from southern and eastern Europe (Bosnia & Herzegovina, Italy, Malta, Moldova and
Poland).
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Incidence of paediatric ulcerative colitis across Europe
Since 2000, the incidence of paediatric UC has ranged across Europe from no cases reported
from Tartu County, Estonia in 2010,21 to 9.5 per 100 000 reported from Corsica, France between
2002 and 2003 (Appendix 3).22 Other studies that have reported high incidence of paediatric UC
refer to the Uppsala region of Sweden (8.9),23 Finland nationally (7.7),24 Denmark nationally
(6.7),12 and the Veszprem province of Hungary (5.2).16
Regionally across Europe, the proportion of studies since 2000 that reported high incidence of
paediatric UC (>2.5 per 100 000) was higher in northern Europe (70% of 20 studies) than in
southern Europe (27% of 11 studies; p=0.031). However, it was not significantly higher than in
eastern Europe (43% of 8 studies; p=0.200) or western Europe (50% of 6; p=0.628). Overall, the
proportion of studies that reported high incidence in northern Europe (70%) was higher than
for the other three regions of Europe combined (36%; p=0.040). The meta analysis in Table 2
and Figure 2b show the highest incidence quintile of paediatric UC in studies from parts of the
four Scandinavian countries and Germany, with lowest incidence in studies from southern and
eastern Europe (Bosnia & Herzegovina, Croatia, Estonia, Italy and Spain).
Of 44 studies since 2000 that have reported both paediatric CD and UC incidence, 34 (77%)
reported higher incidence for CD. Of the other 10 studies, 5 reported equal or similar (+20%)
incidence and the remaining 5 studies – from France, Finland (2), Italy and the Netherlands –
reported higher incidence of UC.
Over time, the mean ratio of paediatric CD to UC incidence has increased significantly from 1.0
(95% CI = 0.6–1.4) for studies conducted during the 1970s and 1980s to 1.9 (1.5–2.3) for those
during the 1990s, but has since fallen slightly to 1.6 (1.3–1.9) for those since 2000.
Incidence of paediatric indeterminate colitis across Europe
The incidence of paediatric indeterminate (or unclassified) colitis, as reported from studies in
Europe has varied from 0 in several studies to 1.5 per 100 000 population reported from the
Netherlands nationally between 1999 and 2001,25 with little clear pattern across Europe
(Appendix 4). The incidence of paediatric indeterminate colitis is often higher in children and
adolescents than in adults, particularly in studies where disease onset peaks at these ages. Over
time a high proportion of indeterminate colitis cases progress with re-classification to either CD,
UC or to other much less common forms of IBD, while symptoms resolve in some cases.
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Incidence of paediatric IBD based on restricted age ranges
Two further studies have reported on paediatric IBD incidence for more restricted age ranges.
These are, firstly, a national study across Ireland from 2000 to 2014 for children aged 0-9 years
(incidence of CD, UC and colitis undetermined = 2.5, 2.1 and 0.6 per 100 000 population
respectively).26 Secondly, a study of CD in Cardiff, Wales which reported an incidence of 1.7 per
100 000 for children aged 10 to 14 years.27
Prevalence of paediatric IBD across Europe
Relatively few studies have reported on population-based prevalence, seven for CD and five for
UC. Reported prevalence for CD has ranged from 8.2 per 100 000 in east Denmark from 1998 to
2000,28 to approximately 60 per 100 000 nationally across Hungary during 2011-2013.29 For
UC, prevalence has varied from 8.3 per 100 000 in east Denmark from 1998 to 2000,28 to
approximately 30 per 100 000 across Hungary during 2011-2013,29 nationally across Sweden in
2010,30 and in Copenhagen County, Denmark in 1978.31
Trends in the incidence of paediatric IBD across Europe
Longitudinal trends in the incidence of paediatric CD since 1970 have been reported from 33
studies, largely from northern Europe (25; Figure 3a) but also from eastern (4), western and
southern Europe (2 each; Figure 3b). All but 3 studies (91%) show increases over time. Largest
increases are evident from Stockholm County and Stockholm during the 1990s (mean annual
increases = 22% and 39% respectively),17,32 south Glamorgan, Wales during the late 1980s
(28% increase),33 the Wessex Region of England from 2005 to 2010 (11%),34 the Pilsen region
of the Czech Republic from 2000 to 2015 (8.9%),35 Denmark nationally from 1997 to 2012
(7.3%),12 and west Hungary (increase from 0 to 7.2 per 100 000 population between 1979 and
2009.36
29 studies have reported on trends over time in paediatric UC incidence, mostly from northern
Europe (21; Figure 4a) and also from eastern (4), western and southern Europe (2 each; Figure
4b). 21 of the 28 studies (75%) reported increases over time, 4 reported reductions in incidence
and 4 reported no trend. The largest increases were from the Czech Republic, 25 centres
(average 33% per annum increase from 1991 to 2001),37 Dublin, Ireland (29% increase) from
2000 to 2010,38 and Stockholm County, Sweden (28%) from 2002 to 2007,14 and from west
Hungary (21.4%) between 1979 and 2009.36
When confining the analysis to the 9 national studies that have reported on longitudinal trends
of CD (Figure 5a), all show overall increases, although the increases were larger during the
earlier study years in three studies, from Finland, Iceland and Scotland. Of the 7 national studies
10
of trends in paediatric UC (Figure 5b), all showed overall increases in incidence, although in 4
cases (Denmark [2], Finland and Iceland), earlier increases in incidence levelled off in more
recent years.
Trends in incidence according to age group at disease onset
Several studies have reported on trends in incidence for paediatric CD and/or UC according to
the age group of the child or adolescent (e.g. very early onset vs later adolescent onset; Figures
6a and 6b). With the exception of a study of UC from south east Norway,39 this evidence shows
more clear increases in incidence – and much higher incidence rates – among adolescent ages
rather than among infants and younger children.
Case ascertainment and study design
Most of the evidence on paediatric IBD incidence and prevalence has been based on individual
studies that have used varying study design methodologies and information sources. These are
detailed in Appendices 2 to 4 for CD, UC and indeterminate colitis respectively. Most studies
were based on records from gastroenterology, paediatric and pathology departments, few
incorporated primary care data.
There have been few multinational studies that have used the same case definitions,
information sources and timescales. A notable exception is the EPICOM inception cohort for IBD
in centres across Europe. The cohort was based on standardised and consistent diagnostic
criteria, time periods of inclusion, and ascertainment methods across each centre. It included
paediatric as well as adult IBD and, with sufficient numbers of paediatric IBD cases to fulfil the
study inclusion and exclusion criteria, it was used to provide incidence data for several
countries in this report.21 40
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Discussion
This study provides a first systematic review of IBD incidence and prevalence focused on all 51
European countries. It has found higher incidence of paediatric IBD in northern Europe than in
other European regions, with a stronger north: south gradient than an east: west gradient (from
higher to lower). It has also identified large increases in the incidence of both paediatric CD and
UC over the last 50 years, which are widespread across Europe. The incidence of paediatric CD
has increased up to 9 or 10 per 100 000 population in parts of Europe, including Scandinavia,
while rates for paediatric UC are often slightly lower than for CD. Studies that have reported on
trends in paediatric IBD incidence according to age group at disease onset have tended to report
sharper increases, as well as much higher incidence, among older age groups rather than for
younger children.
Strengths and limitations
Strengths of this systematic review and meta analysis include the geographical breadth across
51 European countries. The study sought to address possible publication biases by searching
grey literature and hand searching reference lists. The main limitations of the information
sources are firstly that incidence and prevalence data are not compiled routinely. The strongest
evidence is obtained from prospective multinational studies that use consistent clinical
definitions and methodology across centres or from large IBD disease registers with established
case ascertainment techniques, but these are not in place in most countries. Much of the
evidence compiled and used in the meta analyses is therefore drawn from individual studies in
single or networked centres. These centres are often based in large cities and the subjects
included may not be representative of their wider national populations, so that their incidence
rates may also not be representative of their national populations. For example, several studies
have shown that the incidence of paediatric IBD is higher in urban than in rural settings.41,42
There is variation in healthcare systems and methodology used across the many different
studies, in terms of the diagnostic criteria used, the age ranges of the subjects classified as
paediatric and adolescent, the information sources and case ascertainment used and also
whether the studies employed case validation to confirm diagnoses. There have been
improvements over time in clinical diagnostic techniques for paediatric IBD which may have led
some studies to note increases over time in mild cases that may not have been detected in
earlier decades. Hence, this could affect the trends in IBD incidence reported in some studies,
especially during earlier decades, as well as comparisons of incidence across studies. 
Most of the evidence on paediatric IBD incidence in this review has been reported from
northern Europe with relatively few studies from eastern Europe or southern Europe outside
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Italy and Spain. The highest incidence has been reported in studies from Scandinavia along with
northern France, which are some of the areas that have been studied most intensively. The
higher incidence compared with studies in less investigated regions may therefore partly reflect
better developed or established case detection methods. In the meta analysis of incidence across
European countries, although precedence was given to national studies, rates for some
countries were still confined to regional studies, so that the maps presented show countries
shaded only when based on national studies. The meta analysis would also be affected by
variation in country population sizes. In this analysis, there was variation across non-national
studies in the proportions of the national populations covered, which have been specified in the
notes to the maps. Also, in the analysis of incidence according to the age at disease onset,
relatively few studies provided this information, so that the available evidence is limited.
Regional variation in incidence
Although most evidence was available from northern Europe, for both paediatric CD and UC, we
found much stronger evidence of a north: south than an east: west gradient in the incidence of
paediatric IBD with highest rates often in Scandinavia. For adult IBD there is both a strong east:
west as well as a north: south gradient in incidence with highest rates usually in northern or
western regions of Europe.43 The lesser east: west gradient for paediatric IBD review may be
partly due to the smaller evidence base than for adult IBD, its focus on northern Europe and the
lack of paediatric studies from many eastern and southern European countries. Nonetheless, the
higher incidence in more affluent regions of northern and western Europe is consistent with
several studies that have linked paediatric IBD with higher socioeconomic groups.44-46
Trends in incidence
There have been large increases over time in the incidence of both paediatric CD and UC.
Although most of this evidence is from northern Europe, the increases appear widespread
throughout Europe, including both more affluent and lesser developed regions of Europe. For
example, the largest increases have been reported in studies from countries such as Sweden,
Denmark, Hungary, the Czech Republic, Wales and Ireland. The increases in incidence in eastern
European countries may be partly explained by increasing adoption over time of westernized
diets. Incidence of paediatric CD has now reached 9 or 10 per 100 000 in some European
regions, especially in Scandinavia, while incidence for paediatric UC is often slightly lower than
for CD. Outside Europe the highest incidence has been reported from north America and
Australasia.2,47,48
The increases in incidence are still apparent when the analysis of trends was confined to
national studies. The increases are also slightly stronger for paediatric CD than for UC,
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particularly in more recent years when incidence has levelled off after earlier increases. The
latter may reflect improvements over time in diagnostic testing in some studies during earlier
decades. However, in the absence of major background changes in population genetic factors,
the large increases in incidence would indicate the role of environmental factors in the
pathogenesis of IBD. Over time, there was also a significant increase in the ratio of paediatric CD
to UC incidence, although this has fallen slightly during the most recent study years. The
increase is likely to reflect higher rates of upper GI endoscopies over time and consequent
reductions in the misclassification of CD cases.49-52 It may also reflect more widespread diets
high in saturated fat or ‘junk food’ diets, which are thought to be an evolving environmental
trigger in the pathogenesis of IBD and Crohn’s disease in particular.53-56
Trends in incidence according to age at disease onset
Studies that have reported on trends in incidence according to the age group at disease onset,
show larger increases – as well as higher incidence – among older age groups than among
infants and younger children, especially for CD. Although the incidence of paediatric IBD often
increased sharply with age up to 19 and 20 years, many of the studies that reported highest
incidence of were confined to 0-14 or 0-15 year age groups, for example, from Scandinavia,
11,12,14,24 and northern France.13 Studies worldwide have shown that the incidence of both early
and very early onset IBD have been increasing over time, particularly during most recent years,
as the genetic contribution to IBD has become better understood.47,57,58
Prevalence
Few studies have reported on the prevalence of paediatric IBD in Europe and reported rates
vary widely across studies. The variation is probably explained at least partly by differences in
study methodology, particularly differences in study time periods and case ascertainment for
establishing prevalence.
Paediatric IBD is frequently a devastating chronic disease, with incidence rates that are
constantly increasing in most countries and often presents societal challenges. Identification
of high risk populations can help with identifying preferential targeting for studies that focus on
detecting environmental triggers as an important step towards primary prevention strategies.  
Recommendations
• There is a need for more prospective studies, preferably multinational and based on IBD
registries, that use standardised definitions, methodology and timescales. This would enable
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better comparisons of paediatric IBD disease patterns across European countries and across
regions within countries. Specialist clinical information systems should be valuable for
facilitating standardised clinical definitions in prospective studies.
• In view of increases in incidence and prevalence of paediatric IBD, greater resources should
be provided to enable more subspecialty paediatric GI training to improve management of IBD
in childhood. Long-term and gradual transitional arrangements between paediatric care and
adult care should be a key part of the care pathway to ensure the most effective and least
disruptive long-term disease management.
• Improved education and workplace policies that better consider the needs of paediatric IBD
patients and parents and carers of children with IBD should be implemented.
• Children with IBD must be treated by a multidisciplinary team looking not only at the
medical aspects but also at areas related to the patient’s life, such as lifestyle, diet, social and
psychological needs.
• Future studies should seek to incorporate increasingly available electronic hospital clinic
and primary care data which could also help facilitate better understanding of the effects of
therapeutic interventions. Although several registries are currently in place in Europe,21,59-65 a
major pan-European registry of paediatric IBD would greatly improve our ability to identify and
monitor paediatric IBD across Europe. This would require changes in medical policies in some
countries with mandatory reporting of IBD cases.
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Figure 1 PRISMA flow diagram
Potentially relevant studies identified from 
PubMed, CINAHL and the Cochrane Library
n = 3284
Studies included after duplicates removed
n = 2772
Studies included after screening by title
n = 513
Studies included after screening by abstract
n = 278




Studies included from hand searches of
reference lists, grey literature and websites
n = 14
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Table 1 A summary of the numbers of studies and countries regionally across Europe
that are covered for each of the review objectives










1a).    Incidence or prevalence of paediatric
          Crohn's disease since 1970 65   (10) 16   (6) 11    (5) 20   (7)
1b).    Incidence or prevalence of paediatric
          ulcerative colitis since 1970 51   (10) 18   (6) 10    (5) 18   (7)
1c).    Incidence or prevalence of paediatric
          Indeterminate colitis since 1970 23   (10)  7    (3) 5    (3)  5    (2)
2a).    Regional variation in the incidence of
          paediatric Crohn's disease since 2000 21    (9)  7    (5) 9    (5)  12   (4)
2b).    Regional variation in the incidence of
          paediatric ulcerative colitis since 2000 20    (9)  6    (4) 8    (5)  11   (4)
3a).    Trends in the incidence of paediatric Crohn's
          disease since 1970 25    (9)  2    (1) 4    (2)  2    (2)
3b).    Trends in the incidence of paediatric
          ulcerative colitis since 1970 20    (9)  2    (1) 4    (2)  2    (2)
3c).    Trends in the incidence of paediatric Crohn's
          disease since 1970 according to the age
          group at disease onset.  5     (3)  1    (1) 0    (0)   0    (0)
3d).    Trends in the incidence of paediatric
          ulcerative colitis since 1970 according to the
          age group at disease onset.  3     (3)  1    (1) 0    (0)   0    (0)
4).      Incidence or prevalence of paediatric IBD
          since 1970 according to study case
          ascertainment and design 69   (10) 20   (6) 13    (5) 20   (7)
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Table 2 The incidence of paediatric Crohn’s disease across Europe
Quintile
(and incidence
range per 100 000) Country
Details of geographical coverage
(and approximate population coverage
for non-national studies)
For Crohn's disease:
       Quintile  I Moldova Chisinau city (20%)













Quintile IV Scotland National
(4.8-5.9) Austria Styria state (15%)
Germany Saxony state and Obepfalz district  (6%)
Finland National
  Estonia Tartu County (10%)
Quintile V Norway Olso and Akershus (20%)
(6.0+) France Nord, Pas-de-Calais, Somme and (10%)
Seine Maritime departments
Denmark National
Croatia Primorsko-Goranska County  (7%)
  Sweden Uppsala and Stockholm Counties (25%)
For ulcerative colitis:
       Quintile  I Estonia Tartu County (10%)
(<1.0 per 100 000) Bosnia & Herzegovina Tuzla region (15%)
Spain National, 78 centres
Croatia Primorsko-Goranska County  (7%)
  Italy National





Quintile III Malta National
(1.7-2.2) Czech Republic Pilsen and Moravia regions (35%)
Ireland National
Scotland National
  Austria Styria state (15%)
Quintile IV Hungary National
(2.3-3.0) Iceland National
Moldova Chisinau city (20%)
France Nord, Pas-de-Calais, Somme and (10%)
Seine Maritime departments
  Slovenia National
Quintile V Germany Saxony state and Obepfalz district  (6%)
(3.1+) Norway Olso and Akershus (20%)




Figure 2a The incidence of paediatric Crohn’s disease across Europe
Figure 2b The incidence of paediatric ulcerative colitis across Europe
Notes
The blue circles denote the approximate locations of non-national studies. For further details of these studies, see Table 2.
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Figure 3a Trends in the incidence of paediatric Crohn's disease in Northern Europe since 1970
Figure 3b Trends in the incidence of paediatric Crohn's disease in Western, Southern and
Eastern Europe since 1970
Notes:  Patient age ranges (in years) are denoted in brackets.  References for the studies are provided in Appendix 2.
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Figure 4a Trends in the incidence of paediatric ulcerative colitis in Northern Europe since 1970
Figure 4b Trends in the incidence of paediatric ulcerative colitis in Western, Southern and
Eastern Europe since 1970
Notes:  Patient age ranges (in years) are denoted in brackets.  References for the studies are provided in Appendix 3.
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Figure 5a Trends in the incidence of paediatric Crohn's disease across Europe since 1970,
based on national studies 
Figure 5b Trends in the incidence of paediatric ulcerative colitis across Europe since 1970, 
based on national studies
Notes:  Patient age ranges (in years) are denoted in brackets.  References for the studies are provided in Appendices 2 and 3.
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Figure 6a Trends in the incidence of paediatric Crohn's disease across Europe since 1970,
by age group at disease onset 
Figure 6b Trends in the incidence of early onset paediatric ulcerative colitis across Europe 
since 1970, by age group at disease onset 
Notes:  Patient age ranges (in years) are denoted in brackets.  References for the studies are provided in Appendices 2 and 3.
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Appendix 1 Search terms used
1). (incidence OR prevalence) AND (crohn's OR colitis OR inflammatory bowel disease OR IBD) AND
(children OR adolescent OR pediatric OR young) AND (Albania OR Andorra OR Armenia OR
Austria OR Azerbaijan OR Belarus OR Belgium OR Bosnia OR Bulgaria OR Croatia OR Czech*
OR Cyprus OR Denmark OR Estonia OR France OR Germany OR Georgia OR Hungary OR
Iceland OR Ireland OR Italy OR Kazakhstan OR Kosovo OR Latvia OR Lithuania OR Luxembourg
OR Liechtenstein OR Malta OR Moldova OR Monaco OR Macedonia OR Montenegro OR
Netherlands OR Holland OR Norway OR Poland OR Portugal OR Russia OR Romania OR San
Marino OR Slovakia OR Sweden OR Switzerland OR Spain OR Slovenia OR Serbia OR Soviet
OR Turkey OR Ukraine OR Vatican OR Yugoslavia OR England OR Wales OR Scotland OR UK) 
2). (crohn's OR colitis OR inflammatory bowel disease OR IBD) AND (children OR adolescent OR
pediatric OR young) AND (100,000 or million)
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Appendix 2 Incidence and prevalence rates for paediatric Crohn's disease reported across Europe:
studies ordered alphabetically and then in reverse chronological order: studies grouped since 2000 and from 1970 to 1999
Country City / Region
Study information













population Authors & reference
Study periods
since 2000:
Austria Styria HR, Lab, AHD, SPC, Pro, ICV, † 0-19 1997-2007 -- 4.8 -- Petritsch W et al, 2013   66
Bosnia & 
Herzegovina Tuzla region HR, Lab, Ret, ICV, † 0-14 1995-2006 3 0.3 -- Pavlovic-Calic N et al, 2008   10
Croatia Primorsko-Goranska County HR, Lab, Pro, ICV, † 0-19 1995-2001 -- 8 -- Sincić BM et al, 2006   15
Czech Republic Pilsen region HR, Lab, Pro, ICV 0-18 2000-2015 105 6.2 -- Scharwz J, 2017   35
Czech Republic 25 centres HR, Lab, Pro, ICV 0-15 2001 -- 1.3 -- Pozler O et al, 2006   37
Czech Republic Moravia HR, Lab, Ret, ICV 0-14 1998-2001 16 2.7 -- Kolek A et al, 2004   67
2010-2013 -- 7.8 --
2005-2009 -- 6.3 --
Denmark National AHD, Ret 0-16 2000-2004 -- 4.7 -- Larsen MD et al, 2016   12
2008-2013 -- 4.5 --
Denmark National AHD, Ret, † 0-14 2000-2007 -- 3 -- Lophaven SN et al, 2017   68
Denmark Funen & Herlev HR, Lab, Pro, ICV 0-14 2010 6 3.8 -- Burisch J et al, 2014    21
Denmark National AHD, Ret, † 0-14 1995-2012 512 3.0 Nørgård BM et al, 2014   69
Denmark Copenhagen AHD, HR, Ret, † 0-15 2003-2005 -- 2.7 -- Vind I et al, 2006   70
Denmark Eastern HR, AHD, Reg, Pro, ICV 0-14 2002-2004 64 3.1 8.2 Jakobsen C et al, 2008   28
Estonia Tartu County HR, Lab, Pro, ICV 0-14 2010 3 5.6 -- Burisch J et al, 2014   21
2010-2014 251 5.3 --
2005-2009 269 5.6 --
Finland National AHD, Ret 0-15 2000-2004 206 4.1 -- Virta LJ et al, 2017   24
Finland National HR, Lab, Reg, Pro, † 0-14 2000-2007 -- 4 -- Jussila A et al, 2012   71
Finland Helsinki & Tampere HR, Lab, Ret, ICV 0-17 2000-2003 -- 2.6 -- Turunen P et al, 2006   72
North (Nord, Pas-de-Calais, 2006-2011 -- 7.3 --
France Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV 0-16 2000-2005 (1032 in 1988-2011) 5.1 -- Bequet E et al, 2017   13
France Corsica HR, Lab, Pro, ICV 0-19 2002-2003 20 4.1 -- Abakar-Mahamat A et al, 2007   22
Germany Saxony HR, Lab, Reg, Pro, ICV 0-17 2005-2009 18 5.7 -- Zurek M et al, 2018   73
Germany Oberpfalz HR, Lab, Pro, ICV, † 0-14 2004-2006 -- 2.4 -- Ott C et al, 2008   74
Hungary National AHD, Ret 0-19 2011-2013 -- -- ~60 Kurti Z et al, 2016   29
Hungary Veszprem province HR, Lab, Pro, ICV 0-18 2007-2011 95 7.2 -- Lovasz BD et al, 2014   16
32
Hungary National HR, Lab, Pro, ICV 0-17 2007-2009 265 4.7 -- Müller KE et al, 2013   75
Hungary Veszprem province HR, Lab, Pro, ICV, † 0-20 2002-2006 -- 6.6 -- Lakatos L et al, 2011   76
Iceland National HR, Lab, Ret, ICV 0-16 2001-2010 (44 in 1951-2010) 2.3 -- Agnarsson U et al, 2013   77
Iceland National HR, Lab, Ret, ICV, † 0-19 1995-2009 -- 4 -- Björnsson S et al, 2015    78
Ireland Dublin HR, Lab, Ret, ICV 0-15 2000-2010 238 2.3 -- Hope B et al, 2012   38
Italy Northern HR, Lab, Pro, ICV 0-14 2010 1 0.3 -- Burisch J et al, 2014   21
Italy Forli HR, Lab, Ret, ICV, † 0-19 1993-2013 -- 2.5 -- Valpiani D et al, 2018   79
Italy National HR, Lab, Pro, ICV, ‡ 0-17 1996-2003 635 0.8 -- Castro M et al, 2008    80
Moldova Chisinau HR, Lab, Pro, ICV 0-14 2010 1 0.2 -- Burisch J et al, 2014   21
Netherlands National HR, Lab, Pro, ICV 0-17 1999-2001 -- 2.1 -- Van der Zaag-Loonen HJ et al, 2004   25
Norway Akershus HR, Lab, SPC, Pro, ICV 0-17 2005-2007 39 6.8 -- Perminow G et al, 2009   81
Norway Olso HR, Lab, Pro, ICV 0-15 1999-2004 16 3.6 -- Perminow G et al, 2006   39
Poland National AHD, Ret 0-18 2012-2014 -- -- 27 Holko P et al, 2018   82
Poland National HR, Lab, Ret, ICV 0-18 2002-2004 166 0.6 -- Karolewska-Bochenek K et al, 2009   83
Slovenia National HR, Lab, Ret, ICV 0-18 2002-2010 167 4.5 -- Urlep D et al, 2015   84
Slovenia North East HR, Lab, Ret, ICV 0-18 2002-2010 65 4.6 -- Urlep D et al, 2014   85
Slovenia Western HR, Lab, Ret, ICV 0-18 2000-2005 46 2.9 -- Orel R et al, 2009   86
Spain Vigo HR, Lab, Pro, ICV, † 0-14 2010 -- 1.2 -- Fernández A et al, 2015   40
Spain National, 78 centres HR, Ret, † 0-17 2009 -- 1.7 -- Martín-de-Carpi J et al, 2013   87
Spain Madrid HR, Lab, Pro, ICV, † 0-14 2003-2005 -- 2.1 -- López-Serrano P et al, 2009    88
Spain Navarra HR, Lab, Pro, ICV, † 0-14 2001-2003 4 1.7 -- Arin Letamendia A et al, 2008   89
Spain Oviedo HR, Lab, Reg, Pro, ICV, † 0-15 2000-2002 -- 5.8 -- Rodrigo L et al, 2004   90
Sweden National AHD, Ret 0-17 2010 548 -- 29 Ludvigsson JF et al, 2017   30
Sweden Uppsala County HR, Lab, Ret, ICV, † 0-16 2005-2009 -- 10 -- Sjöberg D et al, 2014   11
Sweden Stockholm County HR, Lab, Ret, ICV 0-15 2002-2007 96 9.2 -- Malmborg P et al, 2013   14
Switzerland Canton of Vaud HR, Lab, Ret, ICV, † 0-19 2003-2005 -- -- 20 Juillerat P  et al, 2008   91
2008-2012 151 5.9 --
UK – England Wessex region HR, Lab, Ret 0-16 2002-2006 98 3.8 -- Ashton JJ et al, 2014   34
UK – Scotland National HR, Lab, Pro, ICV 0-15 2003-2008 265 4.8 -- Henderson P et al, 2012   92 
UK – Scotland Tayside HR, Lab, Ret, ICV 0-19 1998-2007 29 5.9 -- Steed H et al, 2010    93
UK – Wales Cardiff HR, Lab, SPC, Ret, ICV, † 0-15 1996-2005 -- 5 -- Gunesh S et al, 2008   94
UK – Wales Cardiff & Vale region HR, Lab, Ret, ICV 0-15 1996-2003 26 3.6 -- Ahmed M et al, 2006    95
Study periods from
1970 to 1999:
Belgium Liège HR, Lab, Pro, ICV, † 0-19 1963-1996 -- 2.2 -- Latour P et al, 1998  96
Croatia Zagreb HR, Lab, SP, Ret, ICV, † 0-14 1980-1989 5 0.2 -- Vucelić B et al, 1991  97
1994-1997 3 0.5 --
Czech Republic Moravia HR, Lab, Ret, ICV 0-14 1990-1993 0 0.0 -- Kolek A et al, 2004   67
Czech Republic 25 centres HR, Lab, Pro, ICV 0-15 1990 -- 0.3 -- Pozler O et al, 2006   37
Denmark Eastern HR, AHD, Reg, Pro, ICV 0-14 1998-2000 44 2.3 6.7 Jakobsen C et al, 2008   28
33
Denmark Eastern HR, Lab, Ret, ICV 0-14 1998-2000 44 2.3 -- Urne FU, Paerregaard A, 2002   98
Denmark National AHD, Ret 0-16 1995-1999 -- 3.7 -- Larsen MD et al, 2016   12
1990-1999 -- 2 --
Denmark National AHD, Ret, † 0-14 1980-1989 -- 1 -- Lophaven SN et al, 2017  68
Denmark Faroe Islands AHD, Ret, † 0-19 1960-2014 -- 4 -- Hammer T et al, 2016  99
Denmark North Jutland County AHD, Ret 0-14 1978-2002 -- 1.5 -- Jacobsen BA et al, 2006   100
Denmark Faroe Islands HR, Lab, SPC, Ret, ICV, † 0-19 1964-1983 -- 2 -- Berner J and Kiaer T, 1986   20
1978 -- -- 10
Denmark Copenhagen County HR, Lab, Ret, ICV, † 0-15 1970-1978 -- 0.2 -- Binder V et al, 1982  31
1987 373 -- 54
Denmark Copenhagen County HR, Lab, Ret, ICV, † 0-19 1979-1987 -- 4.2 -- Munkholm P et al, 1992    101
Denmark Copenhagen County HR, AHD, Ret, ICV 0-14 1962-1987 23 0.2 -- Langholz E et al, 1991   102
1995-1999 -- 2.3 --
1991-1994 -- 1.6 --
Finland Helsinki & Tampere HR, Lab, Ret, ICV 0-17 1987-1990 -- 1.2 -- Turunen P et al, 2006    72
Finland National HR, Lab, Ret, ICV 0-17 1987-2003 449 2.3 -- Lehtinen P et al, 2011   103
France
North (Nord, Pas-de-Calais, 
Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV, † 0-19 1988-1999 -- 3.5 -- Molinié F et al, 2004   104
France
North (Nord, Pas-de-Calais, 
Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV 0-16 1988-2006 689 3.2 -- Gower-Rousseau C et al, 2013   105
North (Nord, Pas-de-Calais, 1994-1999 -- 4.1 --
France Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV 0-16 1988-1993 (1032 in 1988-2011) 3.4 -- Bequet E et al, 2017   13
France
North (Nord, Pas-de-Calais, 
Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV 0-16 1988-1999 367 2.3 -- Auvin S et al, 2005    106
France Brittany HR, Lab, Pro, ICV 0-16 1994-1997 43 1.6 -- Tourtelier Y et al, 2000   107
France
North (Nord, Pas-de-Calais, 
Somme) HR, Lab, Reg, Pro, ICV, † 0-19 1988-1990 -- 3.5 -- Gower-Rousseau C et al, 1994   108
France North (Nord, Pas-de-Calais) HR, Lab, Reg, Pro, ICV 0-16 1988-1989 31 2.1 -- Gottrand F et al, 1991   109
Hungary Veszprem province HR, Lab, Pro, ICV, † 0-20 1977-2001 -- 2.1 -- Lakatos L et al, 2004   36
1991-2000 -- 2.5 --
1981-1990 -- 1.2 --
Iceland National HR, Lab, Ret, ICV 0-16 1971-1980 (44 in 1951-2010) 0.1 -- Agnarsson U et al, 2013    77
Iceland National HR, Lab, SPC, Ret, ICV, † 0-19 1990-1994 -- 4.5 -- Björnsson S et al, 2000   18
Iceland National HR, Lab, Ret, ICV, † 0-19 1980-1989 -- 0.2 Björnsson S et al, 1998   110
Ireland National HR, Lab, Reg, Pro 0-19 1998-1999 -- 2.3 -- Sawczenko A et al, 2003   111
Italy Sicily HR, Lab, Ret, ICV, † 0-19 1987-1989 8 0.6 -- Cottone M et al, 1991   112
Italy Lombardia HR, Lab, SP, Pro, ICV, † 0-14 1990-1993 -- 1.2 -- Ranzi T et al, 1996    113
Italy Eight cities HR, Lab, SPC, Pro, ICV, † 0-19 1989-1992 -- 1.0 -- Tragnone A et al, 1996    114
Malta National HR, Lab, Ret, ICV, † 0-15 1993-2005 -- 0.5 -- Cachia E et al, 2008    115
Netherlands South Limburg HR, Lab, Reg, Pro, ICV, † 0-19 1991-2002 -- 4.0 -- Romberg-Camps JL et al, 2009   116
Netherlands South Limburg HR, Lab, SPC, PCR, Pro, ICV, † 0-14 1991-1995 -- 1.8 -- Russel MG et al, 1998   117
Norway Akershus HR, Lab, Pro, ICV 0-15 1993-1998 8 2.0 -- Perminow G et al, 2006   39
Norway South East HR, Lab, Pro, ICV 0-15 1990-1993 13 2.0 -- Bentsen BS et al, 2002   118
Norway South East HR, Lab, Pro, Ret, ICV 0-15 1990-1993 19 2.7 -- Størdal K et al, 2004    119
Norway South East, 4 counties HR, Lab, Pro, ICV, † 0-14 1990-1993 -- 0.9 -- Moum B et al, 1996   120
34
Norway Fredrikstad HR, Lab, Pro, ICV, † 0-14 1990 -- 0.5 -- Moum B et al, 1995   121
Norway Northern HR, Lab, SPC, Pro, ICV, † 0-19 1983-1986 -- 4 -- Kildebo S et al, 1989   122
Norway Western, 3 counties HR, Lab, SPC, Pro, ICV 0-15 1984-1985 10 2.5 -- Olafsdottir EJ et al, 1989   123
Slovenia Western HR, Lab, Ret, ICV 0-18 1994-1999 36 2.0 -- Orel R et al, 2009    86
Spain National, 78 centres HR, Ret, † 0-17 1996 -- 0.5 -- Martín-de-Carpi J et al, 2013    87
Spain Aragon HR, Lab, Pro, ICV, † 0-14 1992-1994 -- 0.3 -- Lopez Miguel C et al, 1999   124
Spain
Sabadell, Vigo, Mallorca & 
Motril HR, Lab, Pro, ICV, † 0-13 1991-1993 -- 1.6 -- Brulletta E et al, 1998   125
Sweden Stockholm County HR, Lab, Pro, ICV 0-15 1990-2001 102 4.9 -- Hildebrand H et al, 2003   17
Sweden North Stockholm County HR, Lab, Ret, ICV 0-16 1990-1998 50 3.8 -- Askling J et al, 1999   32
1993-1995 -- 1.3 --
Sweden Stockholm HR, Lab, Pro, ICV 0-15 1984-1986 -- 1.2 -- Lindberg E et al, 2000   126
Sweden Göteborg & South West HR, Lab, Ret, ICV 0-15 1983-1987 -- 2.6 -- Hildebrand H et al, 1994   127
187 -- 6.2
Sweden National HR, Lab, Pro, ICV 0-15 1984-1985 51 1.7 -- Hildebrand H et al, 1991  128
1978-1987 -- 3.3 --
Sweden Örebro HR, Lab, Ret, SPC, ICV 0-14 1968-1972 -- 0.7 -- Lindberg E and Jörnerot G, 1991  129
Sweden Stockholm County AHD, Ret, † 0-14 1975-1989 -- 2.4 -- Lapidus A et al, 1997   130
Sweden Umeå and North HR, Lab, Ret, ICV 0-19 1974-1981 49 3.5 -- Nyhlin H, Danielson A, 1986   131
1980 34 -- 41
Sweden Örebro County HR, Lab, Ret, ICV 0-15 1971-1980 34 6.1 -- Lindquist BL et al, 1984   132
Sweden Stockholm County HR, Lab, Ret, ICV 0-14 1970-1974 -- 1.0 -- Hellers G et al, 1979 133
1975-1983 -- 4 --
Sweden Uppsala region AHD, Lab, Ret, † 0-19 1965-1974 -- 4.5 -- Ekbom A et al, 1991   134
Sweden Uppsala & Västmanland HR, Lab, Ret, ICV, † 0-19 1968-1973 -- 2.4 -- Bergman L & Krause U, 1975  135
UK and Ireland National HR, Lab, Reg, Pro 0-15 1998-1999 379 3.1 -- Sawczenko A et al, 2003   111
UK – England National HR, Lab, Reg, Pro 0-15 1998-1999 -- 3.1 -- Sawczenko A et al, 2003   111
UK – England Derby HR, Lab, Ret, ICV, † 0-19 1976-1985 15 3.2 -- Fellows IW et al, 1990   136
UK – England North Tees region HR, Lab, Ret, ICV, † 0-19 1971-1977 3 0.1 -- Devlin HB et al, 1980   137
UK – Scotland National HR, Lab, Reg, Pro 0-15 1998-1999 -- 4.2 -- Sawczenko A et al, 2003   111
UK – Scotland North East HR, Lab, Ret, ICV 0-16 1990-1999 -- 4.4 -- Watson AJM et al, 2002   138
UK – Scotland National HR, Lab, AHD, Ret, ICV 0-16 1995 150 -- 13.7 Armitage E et al, 2001   139
UK – Scotland National HR, Lab, Ret, ICV 0-15 1990-1995 167 2.9 -- Henderson P et al, 2012   92
North -- 3.1 --
South -- 2.1 --
UK – Scotland National AHD, HR, Ret, ICV 0-16 1981-1995 383 2.3 -- Armitage E et al, 2004   44
1981-1992 -- 2.3 --
UK – Scotland National AHD, HR, Ret, ICV, † 0-16 1968-1979 -- 1.1 -- Armitage E et al, 1999 140
UK – Scotland National AHD, HR, Ret, ICV, † 0-15 1968-1983 -- 1.2 -- Barton JR et al, 1989   141
UK – Scotland North East & Northern Isles HR, Lab, Ret, ICV 0-19 1955-1988 146 4.5 -- Kyle J, 1992   142
UK – Scotland North East & Northern Isles HR, Lab, Ret, ICV, † 0-19 1967-1976 -- 2.4 -- Sinclair TS et al, 1983   143
UK – Wales National HR, Lab, Reg, Pro 0-15 1998-1999 -- 3.2 -- Sawczenko A et al, 2003   111
UK – Wales South Glamorgan HR, Lab, Ret, ICV 0-16 1995-1997 20 1.4 -- Hassan K et al, 2000   144
35
1993 -- -- 16.6
1989-1993 -- 3.1 --
UK – Wales South Glamorgan HR, Lab, Ret, ICV 0-15 1983-1988 (21 in 1983-1988) 1.3 -- Cosgrove M, 1996   33
1981-1995 -- 3.1 --
UK – Wales Cardiff HR, Lab, Ret, ICV, † 0-19 1971-1980 -- 1.9 -- Rose JDR et al, 1988   145
UK – Wales Cardiff HR, Lab, SPC, Ret, ICV, † 0-19 1986-1990 -- 2.8 -- Thomas GA et al, 1995   146
UK – N Ireland National HR, Lab, Reg, Pro 0-15 1998-1999 -- 2.4 -- Sawczenko A et al, 2003   111
UK – N Ireland National HR, Lab, Ret, ICV, † 0-19 1966-1973 10 0.3 -- Humphreys WG et al, 1975   147
Notes
Study sources:  HR = Hospital/clinical records;  Lab = Histopathology records;  Reg = Disease register;  SPC = Survey of primary care;  AHD = Administrative hospital data;  PCR = primary care records;
Pro = Prospective surveillance; Ret = Retrospective review; ICV = Individual case validation; ‡ = incidence and/or prevalence are calculated from numbers of cases and population cited; † = incidence and/or
prevalence are calculated from graphs presented in the published papers 
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Appendix 3 Incidence and prevalence rates for paediatric ulcerative colitis reported across Europe:
studies ordered alphabetically and then in reverse chronological order: studies grouped since 2000 and from 1970 to 1999
Country City / Region
Study Information














population Authors & reference
Study periods 
since 2000:
Austria Styria HR, Lab, AHD, SPC, Pro, ICV, † 0-19 1997-2007 -- 2.2 -- Petritsch W et al, 2013   66
Bosnia & 
Herzegovina Tuzla region HR, Lab, Ret, ICV 0-14 1995-2006 2 0.2 -- Salkic NN et al, 2010   148
Croatia Primorsko-Goranska County HR, Lab, Pro, ICV, † 0-19 1995-2001 -- 0.9 -- Sincić BM et al, 2006   15
Czech Republic Pilsen region HR, Lab, Pro, ICV 0-18 2000-2015 48 2.4 -- Scharwz J, 2017   35
Czech Republic Moravia HR, Lab, Ret, ICV 0-14 1998-2001 11 1.8 -- Kolek A et al, 2004   67
2010-2013 -- 7.4 --
2005-2009 -- 7.4 --
Denmark National AHD, Ret 0-16 2000-2004 -- 7.3 -- Larsen MD et al, 2016   12
2008-2013 -- 5 --
Denmark National AHD, Ret, † 0-14 2000-2007 -- 5 -- Lophaven SN et al, 2017   66
Denmark Funen & Herlev HR, Lab, Pro, ICV 0-14 2010 4 2.2 -- Burisch J et al, 2014   21
Denmark National AHD, Ret, † 0-14 1995-2012 428 2.7 -- Nørgård BM et al, 2014   149
Denmark Copenhagen County AHD, HR, Ret, † 0-15 2003-2005 -- 2.4 -- Vind I et al, 2006   70
Denmark Eastern HR, AHD, Reg, Pro, ICV 0-14 2002-2004 70 2.7 10.5 Jakobsen C et al, 2008   28
Estonia Tartu County HR, Lab, Pro, ICV 0-14 2010 0 0 Burisch J et al, 2014   21
2010-2014 366 7.7 --
2005-2009 371 7.7 --
Finland National AHD, Ret 0-15 2000-2004 294 5.9 -- Virta LJ et al, 2017   24
Finland National HR, Lab, Reg, Pro, † 0-14 2000-2007 -- 6 -- Jussila A et al, 2012   71
Finland Helsinki & Tampere HR, Lab, Ret, ICV 0-17 2000-2003 -- 3.9 -- Turunen P et al, 2006   72
North (Nord, Pas-de-Calais, 2006-2011 -- 2.6 --
France Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV 0-16 2000-2005 (343, 1988-2011) 1.5 -- Bequet E et al, 2017   13
France Corsica HR, Lab, Pro, ICV 0-19 2002-2003 49 9.5 -- Abakar-Mahamat A et al, 2007   22
Germany Saxony HR, Lab, Reg, Pro, ICV 0-17 2005-2009 14 4.4 -- Zurek M et al, 2018   73
Germany Oberpfalz HR, Lab, Pro, ICV, † 0-14 2004-2006 -- 1.1 -- Ott C et al, 2008   74
Hungary National AHD, Ret 0-19 2011-2013 -- -- ~30 Kurti Z et al, 2016   29
Hungary Veszprem province HR, Lab, Pro, ICV 0-18 2007-2011 88 5.2 -- Lovasz BD et al, 2014   16
Hungary National HR, Lab, Pro, ICV 0-17 2007-2009 265 2.3 -- Müller KE et al, 2013    75
37
Hungary Veszprem province HR, Lab, Pro, ICV, † 0-20 2002-2006 -- 4.8 -- Lakatos L et al, 2011   76
Iceland National HR, Lab, Ret, ICV 0-16 2001-2010 (61 in 1951-2010) 2.4 -- Agnarsson U et al, 2013    77
Iceland National HR, Lab, Ret, ICV, † 0-19 1995-2009 -- 6 -- Björnsson S et al, 2015   78
Ireland Dublin HR, Lab, Pro, ICV 0-15 2000-2010 129 1.1 -- Hope B et al, 2012   38
Italy Northern HR, Lab, Pro, ICV 0-14 2010 3 1.1 -- Burisch J et al, 2014   21
Italy Forli HR, Lab, Ret, ICV, † 0-19 1993-2013 -- 3.0 -- Valpiani D et al, 2018    79
Italy National HR, Lab, Pro, ICV, ‡ 0-17 1996-2003 810 1.0 -- Castro M et al, 2008   80
Moldova Chisinau HR, Lab, Pro, ICV 0-14 2010 16 2.7 -- Burisch J et al, 2014   21
Netherlands National HR, Lab, Pro, ICV 0-17 1999-2001 -- 1.6 -- Van der Zaag-Loonen HJ et al, 2004   25
Norway Olso HR, Lab, SPC, Pro, ICV 0-17 2005-2007 19 3.6 -- Perminow G et al, 2009    81
Norway Akershus HR, Lab, Pro, ICV 0-15 1999-2004 9 2.1 -- Perminow G et al, 2006    39
Poland National HR, Lab, Ret, ICV 0-18 2002-2004 231 1.3 -- Karolewska-Bochenek K et al, 2009    83
Slovenia National HR, Lab, Ret, ICV 0-18 2002-2010 105 2.9 -- Urlep D et al, 2015   84
Slovenia North East HR, Lab, Ret, ICV 0-18 2002-2010 39 2.8 -- Urlep D et al, 2014   85
Slovenia Western HR, Lab, Ret, ICV 0-18 2000-2005 25 1.6 -- Orel R et al, 2009    86
Spain Vigo HR, Lab, Pro, ICV, † 0-14 2010 -- 4.0 -- Fernández A et al, 2015   40
Spain National, 78 centres HR, Ret 0-17 2009 -- 0.9 -- Martín-de-Carpi J et al, 2013   87
Spain Madrid HR, Lab, Pro, ICV, † 0-14 2003-2005 -- 2.1 -- López-Serrano P et al, 2009    88
Spain Oviedo HR, Lab, Reg, Prov, ICV, † 0-15 2000-2002 -- 1.7 -- Rodrigo L et al, 2004   90
Spain Navarra HR, Lab, Pro, ICV, † 0-14 2001-2003 2 0.9 -- Arin Letamendia A et al, 2008   89
Sweden National AHD, Ret 0-17 2010 585 -- 30 Ludvigsson JF et al, 2017  30
Sweden Uppsala County HR, Lab, Ret, ICV, † 0-16 2005-2009 -- 8.9 -- Sjöberg D et al, 2014    23
Sweden Uppsala County HR, Lab, AHD, Pro, ICV, † 0-19 2005-2007 -- 10 -- Rönnblom A et al, 2010    150
Sweden Stockholm County HR, Lab, Ret, ICV 0-15 2002-2007 29 2.8 -- Malmborg P et al, 2013    14
Switzerland Canton of Vaud HR, Lab, Ret, ICV, † 0-19 2003-2005 -- -- 15 Juillerat P  et al, 2008    91
2008-2012 69 2.7 --
UK – England Wessex region HR, Lab, Ret 0-16 2002-2006 52 2.0 -- Ashton JJ et al, 2014   34
UK – Scotland National HR, Lab, Pro, ICV 0-15 2003-2008 115 2.1 -- Henderson P et al, 2012    92
UK – Wales Cardiff & Vale region HR, Lab, Ret, ICV 0-15 1996-2003 11 1.5 -- Ahmed M et al, 2006    95
Study periods 
from 1970 to 1999:
Belgium Liège HR, Lab, Pro, ICV, † 0-19 1963-1996 -- 1.2 -- Latour P et al, 1998   96
Czech Republic 25 centres HR, Lab, Pro, ICV 0-15 1990-2001 202 0.6 -- Pozler O et al, 2006   37
1994-1997 6 0.9 --
Czech Republic Moravia HR, Lab, Ret, ICV 0-14 1990-1993 5 0.7 -- Kolek A et al, 2004    67
Denmark Eastern HR, AHD, Reg, Pro, ICV 0-14 1998-2000 50 1.8 8.3 Jakobsen C et al, 2008   28
Denmark Eastern HR, Lab, Ret, ICV 0-14 1998-2000 50 1.8 -- Urne FU and Paerregaard A, 2002   98
Denmark National AHD, Ret 0-16 1995-1999 -- 6.9 -- Larsen MD et al, 2016   12
38
1990-1999 -- 3 --
Denmark National AHD, Ret, † 0-14 1980-1989 -- 3 -- Lophaven SN et al, 2017  66
Denmark Faroe Islands AHD, Ret, † 0-19 1960-2014 -- 11 -- Hammer T et al, 2016     99
Denmark North Jutland County AHD, Ret 0-14 1978-2002 -- 2.7 -- Jacobsen BA et al, 2006    100
Denmark Copenhagen County HR, AHD, Ret, ICV 0-14 1962-1987 80 2.0 -- Langholz E et al, 1991    102
1978 -- -- 30
Denmark Copenhagen County HR, Lab, Ret, ICV, † 0-15 1970-1978 -- 2.5 -- Binder V et al, 1982   31
Denmark Faroe Islands HR, Lab, SPC, Ret, ICV, † 0-19 1964-1983 -- 2 -- Berner J and Kiaer T, 1986   20
1995-1999 -- 3.1 --
1991-1994 -- 3.0 --
Finland Helsinki & Tampere HR, Lab, Ret, ICV 0-17 1987-1990 -- 2.1 -- Turunen P et al, 2006   72
Finland National HR, Lab, Ret, ICV 0-17 1987-2003 880 4.5 -- Lehtinen P et al, 2011   103
France
North (Nord, Pas-de-Calais, 
Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV, † 0-19 1988-1999 -- 1 -- Molinié F et al, 2004   104
France
North (Nord, Pas-de-Calais, 
Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV 0-16 1988-2006 213 1.1 -- Gower-Rousseau C et al, 2013   105
France
North (Nord, Pas-de-Calais, 
Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV 0-17 1988-2002 113 0.8 -- Gower-Rousseau C et al, 2009  151
France
North (Nord, Pas-de-Calais, 
Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV 0-16 1988-1999 122 0.8 -- Auvin S et al, 2005    106
North (Nord, Pas-de-Calais, 1994-1999 -- 1.3 --
France Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV 0-16 1988-1993 (343,  1988-11) 1.2 -- Bequet E et al, 2017   13
France Brittany HR, Lab, Pro, ICV 0-16 1994-1997 14 0.6 -- Tourtelier Y et al, 2000     107
France
North (Nord, Pas-de-Calais, 
Somme) HR, Lab, Reg, Pro, ICV, † 0-19 1988-1990 -- 1 -- Gower-Rousseau C et al, 1994   108
France North (Nord, Pas-de-Calais) HR, Lab, Reg, Pro, ICV 0-16 1988-1989 7 0.5 -- Gottrand F et al, 1991    109
Germany
Essen, Duisburg,
Mülheim & Oberhausen HR, Lab, Ret, ICV, † 0-19 1980-1984 -- 0.8 -- Dirks E et al, 1994  152
Greece Trikala HR, Lab, Pro, ICV 0-19 1990-1994 8 3.8 -- Ladas SD et al, 2005   153
Hungary Veszprem province HR, Lab, Pro, ICV, † 0-20 1977-2001 -- 1.2 -- Lakatos L et al, 2004   36
Iceland National HR, Lab, SPC, Ret, ICV, † 0-19 1990-1994 -- 5 Björnsson S et al, 2000    18
1991-2000 2.9 --
1981-1990 1.2 --
Iceland National HR, Lab, Ret, ICV 0-16 1971-1980 (61 in 1951-2010) 0.7 -- Agnarsson U et al, 2013    77
Iceland National HR, Lab, Ret, ICV, † 0-19 1980-1989 -- 0.5 -- Björnsson S et al, 1998    110
Ireland National HR, Lab, Reg, Pro 0-15 1998-1999 -- 2.0 -- Sawczenko A et al, 2003   111
Italy Lombardia HR, Lab, SP, Pro, ICV, † 0-14 1990-1993 -- 1.2 -- Ranzi T et al, 1996    113
Italy Eight cities HR, Lab, SPC, Pro, ICV, † 0-19 1989-1992 -- 1.8 -- Tragnone A et al, 1996    114
Malta National HR, Lab, Ret, ICV, † 0-15 1993-2005 -- 1.7 -- Cachia E et al, 2008    115
Netherlands South Limburg HR, Lab, Reg, Pro, ICV, † 0-19 1991-2002 -- 2.0 -- Romberg-Camps JL et al, 2009   116
Netherlands South Limburg HR, Lab, SPC, PCR, Pro, ICV, † 0-14 1991-1995 -- 0.8 -- Russel MG et al, 1998   117
Norway Akershus area HR, Lab, Pro, ICV 0-15 1993-1998 15 3.7 -- Perminow G et al, 2006    39
Norway South East HR, Lab, Pro, Ret, ICV 0-15 1990-1993 14 2.0 -- Størdal K et al, 2004    119
Norway South East HR, Lab, Pro, ICV 0-15 1990-1993 -- 2.1 -- Bentsen BS et al, 2002    118
Norway Fredrikstad HR, Lab, Pro, ICV, † 0-14 1990 -- 1.1 -- Moum B et al, 1995    121
39
Norway Northern HR, Lab, SPC, Pro, ICV, † 0-19 1983-1986 -- 4.5 -- Kildebo S et al, 1990   154
Norway West, 3 counties HR, Lab, SPC, Pro, ICV 0-15 1984-1985 17 4.3 -- Olafsdottir EJ et al, 1989   123
Slovenia Western HR, Lab, Ret, ICV 0-18 1994-1999 14 0.8 -- Orel R et al, 2009    86
Spain National, 78 centres HD, Ret, † 0-17 1996 -- 0.4 -- Martín-de-Carpi J et al, 2013   87
Spain Aragon HR, Lab, Pro, ICV, † 0-14 1992-1994 -- 0.3 -- Lopez Miguel C et al, 1999   124
Spain
Sabadell, Vigo, Mallorca & 
Motril HR, Lab, Pro, ICV, † 0-13 1991-1993 -- 0.2 -- Brulletta E et al, 1998   125
Sweden Stockholm County HR, Lab, Pro, ICV 0-15 1990-2001 -- 1.7 -- Hildebrand H et al, 2003   17
Sweden North Stockholm County HR, Lab, Ret, ICV 0-16 1990-1998 27 2.1 -- Askling J et al, 1999    32
Sweden Uppsala County HR, Lab, AHD, SPC, Ret, ICV, † 0-19 1964-1983 -- 8 -- Rönnblom A et al, 2010    150
Sweden Göteborg & South West HR, Lab, Ret, ICV 0-15 1983-1987 -- 1.9 -- Hildebrand H et al, 1994    127
1993-1995 -- 3.2 --
Sweden Stockholm HR, Lab, Pro, ICV 0-15 1984-1986 -- 1.4 -- Lindberg E et al, 2000   126
225 -- 7.5
Sweden National HR, Lab, Pro, ICV 0-15 1984-1985 51 1.7 -- Hildebrand H et al, 1991   128
Sweden Ornsköldsvik HR, Lab, Ret, ICV 0-18 1961-2005 46 1.6 -- Lindberg J et al, 2008    155
Sweden Malmo HR, Lab, Ret, ICV 0-19 1958-1982 83 5.1 -- Stewénius J et al, 1995   156
1975-1983 -- 4.8 --
Sweden Uppsala region AHD, Lab, Ret, † 0-19 1965-1974 -- 6.2 -- Ekbom A et al, 1991   134
UK and Ireland National HR, Lab, Reg, Pro 0-15 1998-1999 172 1.4 -- Sawczenko A et al, 2003    111
UK – England National HR, Lab, Reg, Pro 0-15 1998-1999 -- 1.4 -- Sawczenko A et al, 2003    111
UK – England North Tees region HR, Lab, Ret, ICV, † 0-19 1971-1977 13 0.6 -- Devlin HB et al, 1980    137
UK – Scotland Tayside HR, Lab, Ret, ICV 0-19 1988-2007 -- 5.9 -- Steed H et al, 2010   93
UK – Scotland National HR, Lab, Reg, Pro 0-15 1998-1999 -- 1.8 -- Sawczenko A et al, 2003   111
UK – Scotland North East HR, Lab, Ret, ICV 0-16 1990-1999 -- 1.5 -- Watson AJM et al, 2002   138
UK – Scotland National HR, Lab, AHD, Ret, ICV 0-16 1995 101 -- 9.2 Armitage E et al, 2001   139
UK – Scotland National HR, Lab, Ret, ICV 0-15 1990-1995 93 1.6 -- Henderson P et al, 2012    92
North -- 1.3 --
South -- 1.2 --
UK – Scotland National AHD, HR, Ret, ICV 0-16 1981-1995 197 1.3 -- Armitage E et al, 2004   139
UK – Wales National HR, Lab, Reg, Pro 0-15 1998-1999 -- 1.7 -- Sawczenko A et al, 2003    111
UK – Wales South Glamorgan HR, Lab, Ret, ICV 0-16 1995-1997 11 0.8 -- Hassan K et al, 2000    144
1993 -- -- 3.4
1989-1993 -- 0.7 --
UK – Wales South Glamorgan HR, Lab, Ret, ICV 0-15 1983-1988 (7 in 1983-1988) 0.7 -- Cosgrove M, 1996   33
1978-1987 -- 2.0 --
UK – Wales Cardiff HR, Lab, SPC, Ret, ICV, † 0-19 1968-1977 -- 2.4 -- Srivastava ED et al, 1992   157
UK – N Ireland National HR, Lab, Reg, Pro 0-15 1998-1999 -- 1.0 -- Sawczenko A et al, 2003   111
Notes
Study sources:  HR = Hospital/clinical records;  Lab = Histopathology records;  Reg = Disease register;  SPC = Survey of primary care;  AHD = Administrative hospital data;  PCR = primary care records;
Pro = Prospective surveillance; Ret = Retrospective review; ICV = Individual case validation; ‡ = incidence and/or prevalence are calculated from numbers of cases and population cited; † = incidence and/or
prevalence are calculated from graphs presented in the published papers 
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Appendix 4 Incidence and prevalence rates paediatric indeterminate colitis reported across Europe:
studies ordered alphabetically and then in reverse chronological order: studies grouped since 2000 and from 1970 to 1999
Country City / Region
Study Information














population Authors & reference
Study periods 
since 2000:
Czech Republic Pilsen region HR, Lab, Pro, ICV 0-18 2000-2015 17 1.0 -- Scharwz J, 2017   35
Denmark Eastern HR, AHD, Reg, Pro, ICV 0-14 2002-2004 11 0.3 1.5 Jakobsen C et al, 2008   28
Finland Helsinki & Tampere HR, Lab, Ret, ICV 0-17 2000-2003 (83 in 1987-2003) 0.9 -- Turunen P et al, 2006   72
France
North (Nord, Pas-de-Calais, 
Somme, Seine Maritime) HR, Lab, Reg, Pro, ICV 0-16 1988-2011 37 0.3 -- Bequet E et al, 2017   13
Germany Saxony HR, Lab, Reg, Pro, ICV 0-17 2005-2009 3 0.9 -- Zurek M et al, 2018   73
Hungary National HR, Lab, Pro, ICV 0-15 2007-2009 25 0.5 -- Müller KE et al, 2013    75
Iceland National HR, Lab, Ret, ICV 0-16 1991-2000 2 0.3 -- Agnarsson U et al, 2013    77
Ireland Dublin HR, Lab, Pro, ICV 0-15 2000-2010 39 0.3 -- Hope B et al, 2012   38
Italy National HR, Lab, Pro, ICV, ‡ 0-17 1996-2003 131 0.2 -- Castro M et al, 2008   80
Netherlands National HR, Lab, Pro, ICV 0-17 1999-2001 -- 1.5 -- Van der Zaag-Loonen HJ et al, 2004   25
Norway Olso HR, Lab, SPC, Pro, ICV 0-17 2005-2007 4 0.6 -- Perminow G et al, 2009    81
Norway Akershus HR, Lab, Pro, ICV 0-15 1999-2004 0 0.0 -- Perminow G et al, 2006   39
Poland National HR, Lab, Ret, ICV 0-18 2002-2004 144 0.8 -- Karolewska-Bochenek K et al, 2009   83
Slovenia National HR, Lab, Ret, ICV 0-18 2002-2010 105 2.9 -- Urlep D et al, 2015    84
Slovenia North East HR, Lab, Ret, ICV 0-18 2002-2010 3 0.2 -- Urlep D et al, 2014    85
Slovenia Western HR, Lab, Ret, ICV 0-18 2000-2005 14 0.8 -- Orel R et al, 2009   86
Sweden National AHD, Ret 0-17 2010 299 -- 16 Ludvigsson JF et al, 2017  30
2008-2012 22 0.8 --
UK – England Wessex region HR, Lab, Ret 0-16 2002-2006 15 0.6 -- Ashton JJ et al, 2014    34
UK – Scotland National HR, Lab, Pro, ICV 0-15 2003-2008 56 0.9 -- Henderson P et al, 2012   92
UK – Wales Cardiff & Vale region HR, Lab, Ret, ICV 0-15 1996-2003 2 0.3 -- Ahmed M et al, 2006    95
Study periods 
from 1970 to 
1999:
Czech Republic 25 centres HR, Lab, Pro, ICV 0-15 1990-2001 45 0.1 -- Pozler O et al, 2006    37
Czech Republic Moravia HR, Lab, Ret, ICV 0-14 1990-2001 3 0.2 -- Kolek A et al, 2004    67
41
Denmark Eastern HR, AHD, Reg, Pro, ICV 0-14 1998-2000 4 0.2 0.8 Jakobsen C et al, 2008   28
Denmark Eastern HR, Lab, Ret, ICV 0-14 1998-2000 4 0.2 -- Urne FU and Paerregaard A , 2002    98
Denmark Faroe Islands AHD, Ret, † 0-19 1960-2014 -- 3 -- Hammer T et al, 2016   99
1995-1999 -- 1.1 --
1991-1994 -- 0.6 --
Finland Helsinki & Tampere HR, Lab, Ret, ICV 0-17 1987-1990 (83 in 1987-2003) 0.4 -- Turunen P et al, 2006   72
France
North (Nord, Pas-de-Calais, 
Somme, Seine Maritime) HR, Lab, Pro, ICV 0-16 1988-1999 20 0.1 -- Auvin S et al, 2005    106
France Brittany HR, Lab, Pro, ICV 0-16 1994-1997 7 0.3 -- Tourtelier Y et al, 2000     107
France North (Nord, Pas-de-Calais) HR, Lab, Reg, Pro, ICV 0-16 1988-1989 9 0.6 -- Gottrand F et al, 1991    109
1991-2000 2 0.3 --
1981-1990 1 0.1 --
Iceland National HR, Lab, Ret, ICV 0-16 1971-1980 0 0.0 -- Agnarsson U et al, 2013    77
Netherlands South Limburg HR, Lab, Reg, Pro, ICV, † 0-19 1991-2002 -- 0.2 -- Romberg-Camps JL et al, 2009   116
Norway Akershus HR, Lab, Pro, ICV 0-15 1993-1998 0 0.0 -- Perminow G et al, 2006   39
Norway South East HR, Lab, Pro, Ret, ICV 0-15 1990-1993 0 0.0 -- Størdal K et al, 2004     119
Norway West, 3 counties HR, Lab, SPC, Pro, ICV 0-15 1984-1985 0 0.0 -- Olafsdottir EJ et al, 1989   123
Slovenia Western HR, Lab, Ret, ICV 0-18 1994-1999 5 0.3 -- Orel R et al, 2009     86
Sweden Stockholm County HR, Lab, Pro, ICV 0-15 1990-2001 5 0.2 -- Hildebrand H et al, 2003   17
Sweden North Stockholm County HR, Lab, Ret, ICV 0-16 1990-1998 14 1.1 -- Askling J et al, 1999   32
1993-1995 -- 2 --
Sweden Stockholm HR, Lab, Pro, ICV, † 0-15 1984-1986 -- 1 -- Lindberg E et al, 2000   126
1985 127 -- 4.2
Sweden National HR, Lab, Pro, ICV 0-15 1984-1985 41 1.4 -- Hildebrand H et al, 1991  128
Sweden Malmo HR, Lab, Ret, ICV 0-19 1958-1982 24 -- 1.5 Stewénius J et al, 1995  156
UK and Ireland National HR, Lab, Reg, Pro, ICV 0-19 1998-1999 72 0.6 -- Sawczenko A et al, 2003   111
UK – England National HR, Lab, Reg, Pro 0-15 1998-1999 -- 0.7 -- Sawczenko A et al, 2003   111
UK – Scotland National HR, Lab, Reg, Pro 0-15 1998-1999 -- 0.6 -- Sawczenko A et al, 2003   111
UK – Scotland North East HR, Lab, Ret, ICV 0-16 1990-1999 0 0.0 -- Watson AJM et al, 2002   138
UK – Scotland National HR, Lab, Ret, ICV 0-15 1990-1995 0 0.0 -- Henderson P et al, 2012   92
UK – Wales National HR, Lab, Reg, Pro 0-15 1998-1999 -- 0.3 -- Sawczenko A et al, 2003   111
UK – Wales South Glamorgan HR, Lab, Ret, ICV 0-16 1995-1997 7 0.5 -- Hassan K et al, 2000    144
UK – Wales South Glamorgan HR, Lab, Ret, ICV 0-15 1983-1993 0 0.0 -- Cosgrove M, 1996    33
UK – N Ireland National HR, Lab, Reg, Pro 0-15 1998-1999 -- 0.2 -- Sawczenko A et al, 2003   111
Notes
Study sources:  HR = Hospital/clinical records;  Lab = Histopathology records;  Reg = Disease register;  SPC = Survey of primary care;  AHD = Administrative hospital data;  PCR = primary care records;
Pro = Prospective surveillance; Ret = Retrospective review; ICV = Individual case validation; ‡ = incidence and/or prevalence are calculated from numbers of cases and population cited; † = incidence and/or
prevalence are calculated from graphs presented in the published papers 
